✦ LIBER ✦

Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes

✍ Scribed by A. Van Dalen; K.J. Heering; V. Barak; T. Peretz; A. Cremaschi; P. Geroni; M. Gion; S. Saracchini; R. Molina; M. Namer; P. Stieber; C. Sturgeon; R.C.F. Leonard; R. Einarsson

Book ID: 114316832
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 746 KB
Volume: 5
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(96)90126-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pre-treatment serum levels of tumour mar

Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

✍ K.V. Albuquerque; M.R. Price; R.A. Badley; I. Jonrup; D. Pearson; R.W. Blamey; J 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 409 KB

Pegylated liposomal doxorubicin and gemc

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study

✍ Adamo, V; Lorusso, V; Rossello, R; Adamo, B; Ferraro, G; Lorusso, D; Condemi, G; 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 126 KB

Multi-center study evaluating circulatin

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

✍ Seigo Nakamura; Hiroshi Yagata; Shinji Ohno; Hiroshi Yamaguchi; Hiroji Iwata; No 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 207 KB

A multicentre dose-escalating study of c

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

✍ C. Villanueva; A. Awada; M. Campone; J.P. Machiels; T. Besse; E. Magherini; F. D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Phase 3 study comparing the use of docet

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

✍ Edgardo Rivera; Jaime A. Mejia; Banu K. Arun; Rosnie B. Adinin; Ronald S. Walter 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

## Abstract ## BACKGROUND Previous studies have evaluated 3‐week and weekly docetaxel schedules in patients with metastatic breast cancer (MBC). The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and m

A phase II randomized study comparing na

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

✍ M. Ghosn; P. Aftimos; F. S. Farhat; J. G. Kattan; C. Hanna; N. Haddad; F. Nasr; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 447 KB